Abstract
Usage of excipients from natural sources is now the most attractive research areas. Most of the synthetic polymers used in the formulation are detrimental to some extent for the human physiological system. Herbal substitute will be the best choice to minimize long term adverse effect. The purposes of repeated dose toxicity testing are to obtain information about biologic activity of chemicals. In the present study, repeated oral toxicity study of formulation containing metformin 1000mg and sitagliptin 50mg in Swiss albino rats was studied. Microwave assisted acrylamide grafted C. tora is used as a polymer in the formulation.
Rats of both sexes from control and different dose groups (100, 200 and 400 mg/Kg body wt.) exhibited normal body weight gain throughout dosing period. Study protocol was prior approved by animal ethics committee. Combination treatment for 28 days, formulation did not show any significant features of haematological, behavioural, hepatotoxicity and nephrotoxicity in rats. Therefore it can be concluded that the combination using the grafted polymer is safe in these repeated doses in rats.
Keywords: Metformin, sitagliptin, toxicity, Grafted Cassia tora, swiss albino rats.
The Natural Products Journal
Title:Repeated dose Toxicity Study in Rats of the Formulation Containing Metformin and Sitagliptin using Microwave Assisted Acrylamide Grafted Cassia tora as Polymer
Volume: 6 Issue: 2
Author(s): Shubhasis Dan, Nilendra Chatterjee, Pallab Mandal, Anjan Das, Balaram Ghosh and Tapan Kumar Pal
Affiliation:
Keywords: Metformin, sitagliptin, toxicity, Grafted Cassia tora, swiss albino rats.
Abstract: Usage of excipients from natural sources is now the most attractive research areas. Most of the synthetic polymers used in the formulation are detrimental to some extent for the human physiological system. Herbal substitute will be the best choice to minimize long term adverse effect. The purposes of repeated dose toxicity testing are to obtain information about biologic activity of chemicals. In the present study, repeated oral toxicity study of formulation containing metformin 1000mg and sitagliptin 50mg in Swiss albino rats was studied. Microwave assisted acrylamide grafted C. tora is used as a polymer in the formulation.
Rats of both sexes from control and different dose groups (100, 200 and 400 mg/Kg body wt.) exhibited normal body weight gain throughout dosing period. Study protocol was prior approved by animal ethics committee. Combination treatment for 28 days, formulation did not show any significant features of haematological, behavioural, hepatotoxicity and nephrotoxicity in rats. Therefore it can be concluded that the combination using the grafted polymer is safe in these repeated doses in rats.
Export Options
About this article
Cite this article as:
Dan Shubhasis, Chatterjee Nilendra, Mandal Pallab, Das Anjan, Ghosh Balaram and Kumar Pal Tapan, Repeated dose Toxicity Study in Rats of the Formulation Containing Metformin and Sitagliptin using Microwave Assisted Acrylamide Grafted Cassia tora as Polymer, The Natural Products Journal 2016; 6 (2) . https://dx.doi.org/10.2174/2210315506666160503163018
DOI https://dx.doi.org/10.2174/2210315506666160503163018 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents In Vivo Bioluminescence Imaging to Assess Pancreatic Islets
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Immobilized Using Nanotechnology of Electron-Beam Synthesis Regulators of Progenitor Cells Functions: Remedies of New Generation for Regenerative Medicine
Recent Patents on Regenerative Medicine Patent Selections
Recent Patents on Anti-Cancer Drug Discovery New Potent and Selective Inhibitor of Pim-1/3 Protein Kinases Sensitizes Human Colon Carcinoma Cells to Doxorubicin
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Pharmacogenetic Study of CYP2C19 Variation and Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Atherothromboticrisk Patients in Thailand
Current Pharmacogenomics and Personalized Medicine Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency
Current Drug Safety The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Statins as the Controlling Agents for Non-Hodgkin's Lymphomas via Increasing the Casein Kinase 2 Interacting Protein-1: A Hypothesis
Current Drug Discovery Technologies FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry